Arcus Biosciences: Jennifer Jarrett Returns as Chief Operating Officer Portfolio News / Karina Tin October 1, 2020 Arcus Biosciences: Jennifer Jarrett Returns as Chief Operating Officer Read More »
Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies Portfolio News / Karina Tin September 30, 2020 Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies Read More »
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases Portfolio News / Karina Tin September 17, 2020 Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases Read More »
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors Portfolio News / Karina Tin September 16, 2020 Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors Read More »
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies Portfolio News / Karina Tin September 15, 2020 Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies Read More »
Hexagon Bio: This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi Portfolio News / Karina Tin September 15, 2020 Hexagon Bio: This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi Read More »
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies Portfolio News / Karina Tin September 15, 2020 Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies Read More »
Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus Portfolio News / Karina Tin September 14, 2020 Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus Read More »
Casma Therapeutics Announces $50 Million Series B Financing Portfolio News / Karina Tin September 10, 2020 Casma Therapeutics Announces $50 Million Series B Financing Read More »
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study Portfolio News / Karina Tin August 29, 2020 NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study Read More »
